Company’s 36-month beta value is 0.70.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BIOL is 31.91M, and currently, short sellers hold a 1.86% ratio of that floaft. The average trading volume of BIOL on May 06, 2024 was 5.74M shares.
BIOL) stock’s latest price update
Biolase Inc (NASDAQ: BIOL)’s stock price has gone rise by 21.23 in comparison to its previous close of 0.15, however, the company has experienced a 16.11% increase in its stock price over the last five trading days. Accesswire reported 2024-05-06 that LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
BIOL’s Market Performance
BIOL’s stock has risen by 16.11% in the past week, with a monthly rise of 3.90% and a quarterly drop of -74.87%. The volatility ratio for the week is 5.91% while the volatility levels for the last 30 days are 9.28% for Biolase Inc The simple moving average for the past 20 days is 19.51% for BIOL’s stock, with a -90.07% simple moving average for the past 200 days.
Analysts’ Opinion of BIOL
Many brokerage firms have already submitted their reports for BIOL stocks, with The Benchmark Company repeating the rating for BIOL by listing it as a “Speculative Buy.” The predicted price for BIOL in the upcoming period, according to The Benchmark Company is $2 based on the research report published on June 19, 2019 of the previous year 2019.
Singular Research, on the other hand, stated in their research note that they expect to see BIOL reach a price target of $2.50. The rating they have provided for BIOL stocks is “Buy” according to the report published on April 25th, 2017.
WallachBeth gave a rating of “Hold” to BIOL, setting the target price at $2.50 in the report published on May 13th of the previous year.
BIOL Trading at 16.15% from the 50-Day Moving Average
After a stumble in the market that brought BIOL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.45% of loss for the given period.
Volatility was left at 9.28%, however, over the last 30 days, the volatility rate increased by 5.91%, as shares surge +8.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.17% upper at present.
During the last 5 trading sessions, BIOL rose by +5.61%, which changed the moving average for the period of 200-days by -97.87% in comparison to the 20-day moving average, which settled at $0.1478. In addition, Biolase Inc saw -84.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BIOL
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.34 for the gross margin
The net margin for Biolase Inc stands at -0.42. The total capital return value is set at -1.16. Equity return is now at value -888.93, with -56.30 for asset returns.
Based on Biolase Inc (BIOL), the company’s capital structure generated 1.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.82. The debt to equity ratio resting at -69.38. The interest coverage ratio of the stock is -7.6.
Currently, EBITDA for the company is -15.14 million with net debt to EBITDA at -0.72. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 8.97for trailing twelve months and the total asset turnover is 1.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.
Conclusion
In a nutshell, Biolase Inc (BIOL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
